Page 35 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Role of common CXC chemokines in NAFLD

Conflict of interest 8. Takaki A, Kawai D, Yamamoto K. Multiple hits, including
oxidative stress, as pathogenesis and treatment target
The authors declare that they have no competing interests. in non-alcoholic steatohepatitis (NASH). Int J Mol Sci.
2013;14(10):20704-20728.
Author contributions
doi: 10.3390/ijms141020704
Conceptualization: Zhihui Li 9. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ.
Writing – original draft: Zhihui Li Mechanisms of NAFLD development and therapeutic
Writing – review & editing: Zhiyun Chen strategies. Nat Med. 2018;24(7):908-922.
Ethics approval and consent to participate doi: 10.1038/s41591-018-0104-9
Not applicable. 10. Tacke F, Puengel T, Loomba R, Friedman SL. An integrated
view of anti-inflammatory and antifibrotic targets for the
Consent for publication treatment of NASH. J Hepatol. 2023;79(2):552-566.
Not applicable. doi: 10.1016/j.jhep.2023.03.038
11. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From
Availability of data steatosis to cirrhosis. Hepatology. 2006;43(2 Suppl 1):S99-S112.
Not applicable. doi: 10.1002/hep.20973

References 12. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver
disease. Lancet. 2021;397(10290):2212-2224.
1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, doi: 10.1016/S0140-6736(20)32511-3
Henry L. The global epidemiology of nonalcoholic fatty liver
disease (NAFLD) and nonalcoholic steatohepatitis (NASH): 13. Demirtas CO, Yilmaz Y. Metabolic-associated fatty liver
A systematic review. Hepatology. 2023;77(4):1335-1347. disease: Time to integrate ground-breaking new terminology
to our clinical practice? Hepatol Forum. 2020;1(3):79-81.
doi: 10.1097/HEP.0000000000000004
doi: 10.14744/hf.2020.2020.0024
2. Riazi K, Azhari H, Charette JH, et al. The prevalence and
incidence of NAFLD worldwide: A systematic review and meta- 14. Eslam M, Newsome PN, Sarin SK, et al. A new definition
analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851-861. for metabolic dysfunction-associated fatty liver disease:
An international expert consensus statement. J Hepatol.
doi: 10.1016/S2468-1253(22)00165-0
2020;73(1):202-209.
3. Younossi ZM, Golabi P, De Avila L, et al. The global
epidemiology of NAFLD and NASH in patients with type 2 doi: 10.1016/j.jhep.2020.03.039
diabetes: A systematic review and meta-analysis. J Hepatol. 15. Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J,
2019;71(4):793-801. Torimura T. MAFLD enhances clinical practice for liver
disease in the Asia-pacific region. Clin Mol Hepatol.
doi: 10.1016/j.jhep.2019.06.021
2022;28(2):150-163.
4. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of
NAFLD-related HCC: Trends, predictions, risk factors and doi: 10.3350/cmh.2021.0310
prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223-238. 16. Clayton M, Fabrellas N, Luo J, et al. From NAFLD to
MAFLD: Nurse and allied health perspective. Liver Int.
doi: 10.1038/s41575-020-00381-6
2021;41(4):683-691.
5. Paik JM, Kabbara K, Eberly KE, Younossi Y, Henry L, doi: 10.1111/liv.14788
Younossi ZM. Global burden of NAFLD and chronic liver
disease among adolescents and young adults. Hepatology. 17. Ayada I, Van Kleef LA, Alferink LJM, Li P, De Knegt RJ,
2022;75(5):1204-1217. Pan Q. Systematically comparing epidemiological and
clinical features of MAFLD and NAFLD by meta-
doi: 10.1002/hep.32228
analysis: Focusing on the non-overlap groups. Liver Int.
6. Ajmera V, Loomba R. Imaging biomarkers of NAFLD, 2022;42(2):277-287.
NASH, and fibrosis. Mol Metab. 2021;50:101167.
doi: 10.1111/liv.15139
doi: 10.1016/j.molmet.2021.101167
18. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and
7. Guo X, Yin X, Liu Z, Wang J. Non-alcoholic fatty liver management of nonalcoholic fatty liver disease: Practice
disease (NAFLD) Pathogenesis and natural products for guidance from the American association for the study of
prevention and treatment. Int J Mol Sci. 2022;23(24):15489. liver diseases. Hepatology. 2018;67(1):328-357.
doi: 10.3390/ijms232415489 doi: 10.1002/hep.29367

Volume 9 Issue 3 (2025) 27 doi: 10.36922/ejmo.8383